Best Immunotherapy Companies in Pennsylvania, United States
The 46 best Immunotherapy companies in Pennsylvania, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Tmunity Therapeutics.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Pennsylvania
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Tmunity Therapeutics Leveraging the immunological potential of T cells to treat a wide range of diseases | $231M | 81 mo ago | 43 | — | — | — | — |
| 2 | Imvax Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity | $175M | 18 mo ago | 50 | David Andrews Co-Founder & Chief Medical Officer | WordPressMySQLPHP+23 | 21 patents Biodiffusion chambers for advanced cell culture and drug screening applications. | — |
| 3 | Carisma Therapeutics Developer of chimeric antigen receptor macrophages for the treatment of cancer | $142M | 46 mo ago | 34 | Michael Klichinsky Co-Founder and Chief Scientific Officer | DrupalPHPZURB Foundation+22 | — | — |
| 4 | Interius Biotherapeutics Developer of gene therapies for treating multiple diseases | $129M | 26 mo ago | 25 25 → 19 (-24%) | — | — | 101 patents Engineered immune cell therapies and targeted gene delivery using mutant G‑CSF and hepatocyte vectors | — |
| 5 | Adaptimmune Developer of novel cancer immunotherapies to treat cancer and infectious disease | $104M | 142 mo ago | 449 | Adrian Rawcliffe CEO | Apple iCloud MailMicrosoft 365Salesforce+17 | 2 patents Engineered T-cell receptor therapies for targeted cancer immunotherapy | — |
| 6 | Cabaletta Bio Developer of CAAR T cells for B cell-mediated autoimmune diseases | $88M | 91 mo ago | 60 | — | Apache HTTP ServerjQueryFancyBox+9 | — | — |
| 7 | Morphotek Monoclonal antibodies against cancer, inflammatory and infectious diseases. | $80M | 184 mo ago | 104 | — | — | 409 patents Patents concentrated in chemistry & materials | — |
| 8 | Ception Therapeutics Monoclonal antibody (mAb) for eosinophilic inflammatory conditions. | $78M | 230 mo ago | 9 | — | — | — | — |
| 9 | Novasenta Developer of a drug discovery platform for cancer therapies | $55M | 31 mo ago | 20 | Dario Vignali Co-Founder | — | 7 patents Therapeutic antibodies targeting CD161 for immune modulation and related diagnostics | — |
| 10 | Immunome Developer of antibody-based therapeutics for treating cancer | $54M | 63 mo ago | 37 | — | WordPressMySQLPHP+16 | 89 patents Antibody‑drug conjugates and fluorinated benzodiazepine therapeutics for cancer treatment | — |
| 11 | Nuron Biotech Develops vaccines for the prevention and treatment of infectious & neurodegenerative diseases. | $53M | 150 mo ago | 9 | — | — | — | — |
| 12 | Verismo Therapeutics Developer of CAR-T cell therapies for cancer 16Funding top 32%Moat top 39%Tech bottom 43%Global bottom 38% All 6 signals ▾Fundingtop 32% Moattop 39% Techbottom 43% Globalbottom 38% Marketbottom 25% Newsbottom 21% Funding: Raised $50.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 16/100 | $50M | 3 mo ago | 9 | — | WordPressMySQLPHP+18 | — | 1 job opening · 1 partnership |
| 13 | Geneos Therapeutics Developer of tumor-specific neoantigen-targeted personalized immunotherapies | $50M | 34 mo ago | 7 | — | — | — | — |
| 14 | BlueSphere Bio Developer of T-cell therapies to treat cancer | $46M | 67 mo ago | 21 21 → 28 (+33%) | Warren Shlomchik Co-Founder | WordPressApple iCloud MailMySQL+15 | — | — |
| 15 | Tavotek Provider of drug discovery platform for different diseases | $35M | 56 mo ago | 23 | — | — | — | — |
| 16 | SIRPant Developer of cancer-specific immunotherapy for the treatment of solid tumors | $27M | 58 mo ago | 9 | Nathanael Mccurley Co-Founder | — | — | — |
| 17 | Coeptis Therapeutics Developer of cell therapies for the treatment of cancer | $18M | 12 mo ago | 5 | Dave Mehalick Co-Founder | DrupalPHPanime.js+22 | — | — |
| 18 | Seneca Therapeutics Developer of immunotherapeutics for the treatment of cancer | $14M | 20 mo ago | 4 | Paul Hallenbeck Founder and Chief Executive Officer | — | — | — |
| 19 | Neotropix Natural health solutions: exercise, diet, meditation, and remedies | $11M | 207 mo ago | 9 | Peter Lanciano ex-CEO | — | 11 patents Patents concentrated in health & consumer products | — |
| 20 | Vittoria Biotherapeutics Developer of T-cell therapies to address various medical conditions | $9M | 60 mo ago | 8 | Marco Ruella Co-Founder | — | 6 patents Engineering and manufacturing CD5-targeted CAR-T cells for immunotherapy | — |
| 21 | Cytoagents Provider of pharmaceutical products for the treatment of viral infectious diseases | $7M | 10 mo ago | 4 | — | — | 30 patents CAR‑T cell adjuvant agents and bispecific antibody therapeutics for immunotherapy | — |
| 22 | Navrogen Developer of cancer immunotherapies and adjuvants for antibodies | $7M | 26 mo ago | 4 | Luigi Grasso Co-Founder | — | 38 patents Patents concentrated in chemistry & materials | — |
| 23 | VGX Pharmaceuticals DNA-based vaccines for cancer and infectious diseases | $4M | 214 mo ago | — | David Weiner Co-Founder | — | — | — |
| 24 | Aevi Genomic Medicine Therapeutics for rare diseases in areas of neurology and hematology. | $4M | 108 mo ago | 3 | — | — | — | — |
| 25 | Duo Oncology Developer of nanoparticle-based drugs for the treatment of cancer | $4M | 14 mo ago | 3 | — | — | — | — |
| 26 | Tavanta Developer of drug for debilitating multiple medical conditions | $4M | 175 mo ago | 12 | Lynne Powell CEO | — | — | — |
| 27 | Man’s Best Friends Therapeutics Developer of vaccines for animal health | $3M | 55 mo ago | 6 | Thomas Tillett CEO & President | — | — | — |
| 28 | Aclipse Therapeutics Developer of antibodies for the treatment of neurogenerative diseases | $3M | 51 mo ago | 7 | Ning Shan Co-Founder & CSO | — | — | — |
| 29 | CellVax Therapeutics Developer of cell-based cancer immunotherapy | $2M | 22 mo ago | 8 | Fernando Kreutz CEO | — | — | — |
| 30 | Chimeron Developer of nucleic acid-based therapeutic solutions for treating cancer | $2M | 28 mo ago | 12 | — | WordPressMySQLPHP+23 | — | — |
| 31 | Alteris Therapeutics US-based biotech developing cancer therapeutic vaccine, acquired by Celldex in 2005 | $900K | — | — | Donald O'Rourke Co-Founder | — | — | — |
| 32 | Immunotope Biotechnology company developing immunotherapies for cancer and chronic viral infections | $700K | 170 mo ago | — | Ramila Philip Founder & President | — | 65 patents Therapeutic cancer vaccines and dengue virus vaccine platforms using cytotoxic T‑cell immunogens | — |
Top 12 Immunotherapy companies in Pennsylvania
#1
Series A · Philadelphia, Pennsylvania · founded 2020 · 9 employees$50Mraised▾
Developer of CAR-T cell therapies for cancer. The KIR-CAR cell therapy provides stimulation to the cell that enhances the T-cell activation and elimination of antigen-negative tumor cells. It provides a product SynKIR-meso for pancreatic cancer, ovarian cancer, and mesothelioma.
- Apr 2026Series A$28M
- Jul 2023Seed$19.2M
- Feb 2023Seed$7M
- Apr 2021Seed$16M
#2
Series C · Philadelphia, Pennsylvania · founded 2015 · 50 employees$174.8Mraised▾
Personalized immunotherapies targeting solid tumors, stimulating innate and adaptive immunity. This biopharmaceutical company is dedicated to turning the complexity of solid tumors against themselves through personalized, whole tumor-derived immunotherapies. Their unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate and adaptive immunity against remaining tumor cells. They are developing a diverse pipeline of personalized treatments with promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors. The company focuses on research & development strategy and activities, clinical development, and potential product development to deliver therapies targeting solid tumors. They are committed to innovation in the field of personalized immunotherapy.
- Jan 2025Series C$29M
- Sep 2023Series C$23M
- Jul 2020Series C$112.4M
- May 2019Series B$24.8M
#3
Public · Wexford, Pennsylvania · founded 2016 · 5 employees$17.5Mraised▾
Developer of cell therapies for the treatment of cancer. The company is developing a CAR-T cell therapy technology and an in vitro diagnostic platform for targeting CD38-related cancers.
- Jul 2025Post IPO$4M
- Feb 2025Post IPO$5.7M
- Jun 2024Post IPO$4.3M
- Oct 2023Post IPO$2M
#4
Series A · Pittsburgh, Pennsylvania · founded 2018 · 4 employees$7.3Mraised▾
Provider of pharmaceutical products for the treatment of viral infectious diseases. The company's lead drug candidate modulates the body’s immune response to reduce tissue damage caused by an excessive immune reaction. The drug candidate would decrease the tissue damage resulting from the excessive release of pro-inflammatory cytokines, known as the cytokine release syndrome, which is induced by influenza and other viral infections.
- Oct 2025Grant (prize money)$2.2M
- Sep 2024Grant (prize money)$994.9K
- May 2023Series A$7M
- Mar 2021Grant (prize money)$2M
#5
Series A · Blue Bell, Pennsylvania · founded 2015 · 4 employees$14.4Mraised▾
Developer of immunotherapeutics for the treatment of cancer. The company's primary asset, SVV-001, is an oncolytic virus that selectively replicates in tumor cells expressing the TEM8 receptor, while being non-pathogenic in both humans and animals. It also offers pipeline of SVV-012 and SVV-005 for various solid cancers.
- Dec 2024Series A$1.6M
- Dec 2022Series A$7.7M
- Dec 2021Series A$5M
- Jun 2020Seed$501K
#6
Seed · Pittsburgh, Pennsylvania · founded 2020 · 3 employees$4.3Mraised▾
Developer of nanoparticle-based drugs for the treatment of cancer. The company's lead candidate includes DUO-207: Gemcitabine Paclitaxel Nanoparticles for multiple tumour types and can be used in combination with immune checkpoint therapies. Its also developing other drug candidates to treat pancreatic cancer, bile duct cancer and relapsed metastatic disease.
- Jun 2025Seed$400K
- Aug 2024Grant (prize money)$400K
- Mar 2024Grant (prize money)$450K
- Jan 2023Seed$4.3M
#7
Acquired · Philadelphia, Pennsylvania · founded 2020 · 25 employees$129Mraised▾
Developer of gene therapies for treating multiple diseases. It is developing cell therapy by using lentiviral pseudotyping that enhances the efficiency of gene therapy. It transforms cells through the in-vivo generation of therapeutic immune and blood cells including Chimeric Antigen Receptor T Cells (CAR-T) for cancers, regulatory T Cells (Treg) for autoimmune diseases, and CD34+ hematopoietic stem cells (HSC) for blood disorders.
- May 2024Series A$51.4M
- Oct 2023Conventional Debt$21.5M
- May 2021Series A$76M
- Mar 2020Seed$1.6M
#8
Series A · Pittsburgh, Pennsylvania · founded 2018 · 20 employees$55Mraised▾
Developer of a drug discovery platform for cancer therapies. The company has developed a proprietary computational platform for single-cell RNA-based analysis of high-quality, human tumor samples. The company’s pipeline includes three programs representing the next generation of immuno-oncology targets and drug candidates.
- Dec 2023Series A$15M
- Jul 2022Series A$40M
#9
Series A · Plymouth Meeting, Pennsylvania · founded 2016 · 7 employees$49.5Mraised▾
Developer of tumor-specific neoantigen-targeted personalized immunotherapies. The company is developing tumor-specific neoantigen-targeted (TSNA-targeted) personalized immunotherapies (immune checkpoint inhibitors such as anti-PD1/PDL1 molecules). Through their patent-protected and proprietary immunotherapy design, they are developing their lead product which is in phase III clinical trial used for treating head and neck cancer, cervical dysplasia, and HIV.
- Sep 2023Series A$5M
- Apr 2023Series A$5M
- Mar 2022Series A$17M
- Nov 2020Series A$12M
#10
Public · Philadelphia, Pennsylvania · founded 2016 · 34 employees$142Mraised▾
Developer of chimeric antigen receptor macrophages for the treatment of cancer. The company has genetically engineering patient macrophages to create chimeric antigen receptor macrophages (CARMA). The company is focussing on solid tumor indications including recurrent ovarian cancer and HER2-overexpressing malignancies.
- Sep 2022Post IPO$30M
- Jan 2021Post IPO$59M
- Jul 2019Post IPO$53M
- Apr 2017Post IPO$3.9M
#11
Acqui-Hired · Philadelphia, Pennsylvania · founded 2015 · 43 employees$231Mraised▾
Tmunity Therapeutics, co-founded by the University of Pennsylvania (Penn), the Perelman School of Medicine at Penn and the University of Pennsylvania Health System, is focused on leveraging the immunological potential of T cells to treat a wide range of diseases. Tmunity is developing novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), universal engineered T cell platforms, and Chimeric Antigen Receptor (CAR) therapies to control T cell activation and direction in vivo, as well as proprietary technologies to activate, expand, and genetically engineer T cells from peripheral blood, cord blood and tumors. The company is rapidly advancing personalized next-generation immunotherapies for oncology, infectious diseases and autoimmune disease toward the clinic. In addition, Tmunity has secured its own manufacturing facility in Norristown, PA, that will enable process improvement and production scale-up to support future multi-center clinical studies across diverse therapeutic indications.
- Oct 2019Series B$75M
- Apr 2018Series A$35M
- Jan 2018Series A$100M
- Jan 2018Series A$5M
#12
Seed · Philadelphia, Pennsylvania · founded 2020 · 8 employees$2.1Mraised▾
Developer of cell-based cancer immunotherapy. It offers a lead product FK-PC101, for the treatment of prostate cancer based on its proprietary technology using the patient's own cancer cells to create specific tumor-presenting cells.
- Sep 2024Seed$2.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology in Pennsylvania is moving
A read on the academic research around Immunology in Pennsylvania — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 353 papers.
- University of Pennsylvania262
- California University of Pennsylvania56
- Hospital of the University of Pennsylvania39
- Pennsylvania State University16
- University of Pennsylvania Health System4
- Immunotherapy11→23
- Cancer2→12
- Chimeric antigen receptor15→22
- Tumor microenvironment2→8
- Autoimmunity1→5
- Immune system6→30
- Immunotherapy16→36
- Oncology2→15
- T cell1→13
- Tumor microenvironment1→11
- Immune system2→14
- Immunotherapy4→13
- Clinical trial1→9
- Internal medicine1→5
- T cell1→4
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.